RxCell is at the forefront of biotechnology, specializing in the development of therapeutic applications utilizing induced pluripotent stem cells (iPSC). The company focuses on creating retinal progenitor cells derived from therapeutic-grade iPSC master cell banks (MCB), which are produced under current good manufacturing practice (cGMP) standards. This commitment to high-quality production ensures that their cell lines are suitable for clinical applications. RxCell is currently advancing its research by manufacturing retinal progenitor cells from one of its iPSC MCBs, which is a crucial step in their process of seeking an investigational new drug (IND) application with the FDA.

The innovative work at RxCell is driven by a passion for regenerative medicine, particularly in the area of retinal cell therapy. By leveraging the unique properties of iPSC technology, the company aims to develop effective treatments for retinal diseases. Their focus on therapeutic-grade cell lines not only enhances the safety and efficacy of their products but also positions RxCell as a leader in the field of regenerative medicine, with the potential to significantly impact patient care in ophthalmology and beyond.

United States

RxCell is a biotechnology company that specializes in the development of advanced cell-based therapies for the treatment of various diseases and medical conditions.

RxCell

Company Details